These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2496554)

  • 1. Serum cholesterol and triglycerides in hematological malignancies.
    Marini A; Carulli G; Azzarà A; Grassi B; Ambrogi F
    Acta Haematol; 1989; 81(2):75-9. PubMed ID: 2496554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinico-hematological characteristics of acute transformation of chronic myeloproliferative syndromes].
    Hernández JM; San Miguel JF; González M; Moraleda JM; Moro MJ; Hernández J; Cuesta B; López Borrasca A
    Med Clin (Barc); 1991 Sep; 97(10):369-72. PubMed ID: 1745085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hypocholesterolemia and other lipoprotein disorders in myelofibrosis].
    Kiss A; Telek B; Rák K
    Orv Hetil; 1994 Nov; 135(48):2643-6. PubMed ID: 7808738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopathologic findings in the myeloproliferative disorders.
    Dickstein JI; Vardiman JW
    Semin Oncol; 1995 Aug; 22(4):355-73. PubMed ID: 7638633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Megakaryocytopoiesis in myeloproliferative disorders].
    Podolak-Dawidziak M
    Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
    [No Abstract]   [Full Text] [Related]  

  • 6. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
    Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
    Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The splenomegaly of myeloproliferative and lymphoproliferative disorders: splenic cellularity and vascularity.
    Zhang B; Lewis SM
    Eur J Haematol; 1989 Jul; 43(1):63-6. PubMed ID: 2767243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypocholesterolemia in myeloproliferative disorders.
    Spanos GA; Bajaj K; Rosner F
    Arch Intern Med; 1981 Jan; 141(1):137-8. PubMed ID: 6934710
    [No Abstract]   [Full Text] [Related]  

  • 9. Granulocyte dysfunction in hematological disorders.
    Matzner Y
    Cancer Invest; 1992; 10(2):155-61. PubMed ID: 1551025
    [No Abstract]   [Full Text] [Related]  

  • 10. Serum erythropoietin titers in hematological malignancies and related diseases.
    Urabe A; Mitani K; Yoshinaga K; Iki S; Yagisawa M; Ohbayashi Y; Takaku F
    Int J Cell Cloning; 1992 Nov; 10(6):333-7. PubMed ID: 1460322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian Multi-Center case-control study.
    Bianco E; Marcucci F; Mele A; Musto P; Cotichini R; Sanpaolo MG; Iannitto E; De Renzo A; Martino B; Specchia G; Montanaro M; Barbui AM; Nieddu R; Pagano L; Rapicetta M; Franceschi S; Mandelli F; Pulsoni A;
    Haematologica; 2004 Jan; 89(1):70-6. PubMed ID: 14754608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow biopsy (BMB). II. Bone marrow biopsy in myeloproliferative disorders.
    Macavei I; Galatâr N
    Morphol Embryol (Bucur); 1989; 35(2):117-27. PubMed ID: 2529429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of interferon in the treatment of chronic myeloproliferative disorders].
    Robak T
    Acta Haematol Pol; 1992; 23(2 Suppl 1):30-7. PubMed ID: 1488870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of hypocholesterolemia in myeloproliferative disease. Relation to disease manifestations and activity.
    Gilbert HS; Ginsberg H; Fagerstrom R; Brown WV
    Am J Med; 1981 Oct; 71(4):595-602. PubMed ID: 7282748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum cholesterol and apoprotein B levels and serum cholinesterase activity in selected hematologic malignancies.
    Cucuianu A; Malide D; Petrov L; Patiu M; Vlaicu S; Cucuianu M
    Rom J Intern Med; 1992; 30(4):261-8. PubMed ID: 1299417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in the mitogenic activity of platelet-derived growth factor(s) in patients with myeloproliferative disease.
    Caenazzo A; Pietrogrande F; Polato G; Piva E; Masiero M; Sgarabotto D; Girolami A
    Acta Haematol; 1989; 81(3):131-5. PubMed ID: 2496560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera.
    Silva M; Richard C; Benito A; Sanz C; Olalla I; Fernández-Luna JL
    N Engl J Med; 1998 Feb; 338(9):564-71. PubMed ID: 9475763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of beta-catenin in chronic myeloproliferative disorders.
    Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
    Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelets and thrombosis in myeloproliferative diseases.
    Harrison CN
    Hematology Am Soc Hematol Educ Program; 2005; ():409-15. PubMed ID: 16304412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.